These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8768738)

  • 1. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
    Schuh KJ; Walsh SL; Bigelow GE; Preston KL; Stitzer ML
    J Pharmacol Exp Ther; 1996 Aug; 278(2):836-46. PubMed ID: 8768738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Jan; 248(1):127-34. PubMed ID: 2913267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone.
    Shannon HE; Cone EJ; Gorodetzky CW
    J Pharmacol Exp Ther; 1984 Jun; 229(3):768-74. PubMed ID: 6547177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):485-91. PubMed ID: 2760839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation.
    Teoh SK; Mendelson JH; Mello NK; Kuehnle J; Sintavanarong P; Rhoades EM
    J Clin Psychopharmacol; 1993 Apr; 13(2):87-99. PubMed ID: 8463453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids.
    Barrett AC; Cook CD; Terner JM; Craft RM; Picker MJ
    Psychopharmacology (Berl); 2001 Nov; 158(2):154-64. PubMed ID: 11702089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine effects on morphine- and cocaine-induced subjective responses by drug-dependent men.
    Teoh SK; Mello NK; Mendelson JH; Kuehnle J; Gastfriend DR; Rhoades E; Sholar W
    J Clin Psychopharmacol; 1994 Feb; 14(1):15-27. PubMed ID: 8151000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
    Foltin RW; Fischman MW
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1153-64. PubMed ID: 8819498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II.
    Kirby KC; Stitzer ML; Heishman SJ
    J Pharmacol Exp Ther; 1990 Nov; 255(2):730-7. PubMed ID: 2243350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficacy of buprenorphine, nalbuphine and morphine in opioid-treated rhesus monkeys discriminating naltrexone.
    Sell SL; McMahon LR; France CP
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1167-73. PubMed ID: 12766254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
    Cichewicz DL; Welch SP
    J Pharmacol Exp Ther; 2003 Jun; 305(3):812-7. PubMed ID: 12606610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.